x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Beyond Biotech - the podcast from Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what"s happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

news tech news

All Episodes

24:44

The future of combination vaccines

Beyond Biotech - the podcast from Labiotech ·

2024/08/30

The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly improve public health preparedness.Moderna is harnessing the power of its mRNA platform to develop vaccines that target multiple respiratory viruses at once, including COVID-19, RSV, and influenza. The breakthrough technology enables the immune system to ...

en-us

18:35

Radiopharma company Pentixapharm to be spun off as it...

Beyond Biotech - the podcast from Labiotech ·

2024/08/23

Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separate company. Pentixapharm’s clinical pipeline includes PENTIXATHER, am Yttrium-90 based therapeutic against CNS lymphoma, and PENTIXAFOR, a Gallium-68 based companion diagnostic. Additionally, PENTIXAFOR is being developed as a diagnostic tool for primary aldosteronism (PA), a significant ...

en-us

36:36

Challenging the European biotech funding status quo

Beyond Biotech - the podcast from Labiotech ·

2024/08/16

There are many questions when it comes to setting up a biotech company, and raising funds. Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. Does a company’s location affect fundraising? What is the best approach to successfully raise funds? What are the current trends in biotech funding?To look at questions surrounding the state of European biotech funding, and how it compares with the global scene, intellectual property, an...

en-us

32:57

[Rebroadcast] Epigenetic editing – the power of...

Beyond Biotech - the podcast from Labiotech ·

2024/08/09

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA.The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. This week, we discu...

en-us

38:40

[Rebroadcast] How does AI assist drug discovery?

Beyond Biotech - the podcast from Labiotech ·

2024/08/02

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time.A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed ...

en-us

25:34

The first mass-market cell therapy?

Beyond Biotech - the podcast from Labiotech ·

2024/07/26

Aurion Biotech is a US biotech with a regenerative medicine platform, developing novel therapies to restore vision to millions of people in need. This week on the podcast, we have a conversation with CEO Greg Kunst about Aurion’s pipeline, and how the company’s treatment could be the first mass-market cell therapy available.The FDA has granted the company BTD and RMAT designations for AURN001 -- the first-ever allogeneic cell therapy candidate in development to restore vision in patients...

en-us

26:13

Cutting through the AI hype in drug discovery

Beyond Biotech - the podcast from Labiotech ·

2024/07/19

LabGenius is a drug discovery company developing next-generation therapeutic antibodies. The company’s discovery platform, EVA, integrates several technologies drawn from the fields of artificial intelligence (AI), robotic automation and synthetic biology. LabGenius operates under a hybrid business model that involves partnering with large biotech and pharma companies while pursuing its own wholly-owned therapeutic pipeline.The company recently closed a £35 million Series B financi...

en-us

29:22

How biotechs are revolutionizing acute on-chronic...

Beyond Biotech - the podcast from Labiotech ·

2024/07/12

Acute on-chronic liver failure (ACLF) is a significant healthcare issue with high unmet needs for patients and clinicians, and a massive burden for healthcare systems. It cost more than $6bn in the US alone in 2021, with a drastic increase over the last 10 years. Genfit is a late-stage biopharma company taking on rare, life-threatening liver diseases with a range of therapeutic targets based on pathophysiology. The company has five assets in its portfolio, from preclinical up to phase 2....

en-us

39:43

The radiotherapeutics boom

Beyond Biotech - the podcast from Labiotech ·

2024/07/05

The field of radiotherapeutics is a hot topic currently, and so who better to talk about the subject than Ken Herrmann, a radiopharmaceutical academic expert, who is Professor of Nuclear Medicine at the Universitätsklinikum Essen, in Essen Germany, and two people from the company Molecular Partners: Patrick Amstutz, who is a co-founder and the CEO, and Dani Steiner, SVP of R&D.Molecular Partners recently shared a preclinical package supporting MP0712, its radioligand candidate. Based on t...

en-us

30:05

Priovant - finding options to treat autoimmune diseases

Beyond Biotech - the podcast from Labiotech ·

2024/06/28

US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL6, IL12, and IL23—with a single, targeted therapy. Brepocitinib has generated positive data in ...

en-us

28:09

How ADCs can deliver death cap mushroom toxins to...

Beyond Biotech - the podcast from Labiotech ·

2024/06/21

Heidelberg Pharma is a clinical stage biotech company developing antibody drug conjugates (ADCs).Its lead amanitin-based ADC product candidate, HDP-101, targets relapsed or refractory multiple myeloma. HDP-101 recently received orphan drug designation; it is currently in a phase I/IIa clinical trial, demonstrating first signs of clinical efficacy. The company is also expanding its therapeutic product pipeline with a further four programs across a variety of malignant hematologic and soli...

en-us

23:40

Looking to cure Type 1 diabetes

Beyond Biotech - the podcast from Labiotech ·

2024/06/14

Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. It has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation. DIAGNODE-3, a confirmatory phase 3 trial, uses injections into a superficial lymph node can to optimize the treatment response.&...

en-us

29:17

Developing treatments for rare pediatric diseases

Beyond Biotech - the podcast from Labiotech ·

2024/06/07

Rare diseases affect around 1 in 2,000 people. Many of the thousands of rare diseases are difficult to diagnose. Of the known rare diseases, about 80% have genetic causes. Leukodystrophies are a group of rare genetic disorders for which there is currently no curative therapy.This week on the podcast we are discussing novel treatments of rare pediatric diseases in a conversation with Dan Williams, CEO, executive director and co-founder of Synaptix Bio. Synaptix Bio is working on developi...

en-us

31:00

Can cell therapy tackle hearing loss?

Beyond Biotech - the podcast from Labiotech ·

2024/05/31

Hearing loss is a huge – and growing – global challenge.Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant global medical challenge. The company’s lead asset, Rincell-1, is designed to regenerate auditory neurons and provide a novel treatment for patients with severe-to-profound age-related hearing loss or auditory neuropathy. The company is looking to st...

en-us

28:50

How biotech is tackling myasthenia gravis

Beyond Biotech - the podcast from Labiotech ·

2024/05/24

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles. It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older. To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a c...

en-us

27:22

Antisense oligonucleotides

Beyond Biotech - the podcast from Labiotech ·

2024/05/17

German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications.The company’s lead compound, ISTH0036, is in clinical development in ophthalmology.On the podcast this week we chat with René Rückert, chief opera...

en-us

21:02

Making waves in cardiovascular disease treatment

Beyond Biotech - the podcast from Labiotech ·

2024/05/10

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised.This week, we have a conversation with the CEO of Cytokinetics, Robert Blum, about the company’s aficamten, its next-in-class cardiac myosin inhibitor, prior to results from a phase 3 clinica...

en-us

23:56

New ways to treat Duchenne muscular dystrophy

Beyond Biotech - the podcast from Labiotech ·

2024/05/03

en-us

26:00

Overcoming clinical trial challenges

Beyond Biotech - the podcast from Labiotech ·

2024/04/26

en-us

28:32

The biotech investment landscape in 2024

Beyond Biotech - the podcast from Labiotech ·

2024/04/19

en-us

172 results

Similar Podcasts

Expres Ráno

Expres FM

PBS News Hour - Full Show

PBS NewsHour

CD Voice

China Daily

Israel Today: Ongoing War Report

Noa Levi

Jeffrey Epstein: The Coverup Chronicles

Bobby Capucci